Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LENZ Therapeutics

Trading 03-26 11:11:07 EDT

25.50

-0.93

-3.52%

High26.96	Low25.17	Vol27.48K
Open26.23	D1 Closing26.43	Amplitude6.79%
Mkt Cap702.34M	Tradable Cap321.54M	Total Shares27.54M
T/O703.30K	T/O Rate0.22%	Tradable Shares12.61M
P/B3.44	ROE-38.94%	EPS-2.34
52wk High38.93	52wk Low14.42	P/E-10.90
Dividend0.00	Div.Yield0.00	ROA-25.64%

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":25.5,"timestamp":1743001854765,"preClose":26.43,"halted":0,"volume":27482,"delay":0,"floatShares":12609337,"shares":27542874,"eps":-2.338654,"marketStatus":"Trading","change":-0.93,"latestTime":"03-26 11:11:04 EDT","open":26.23,"high":26.964,"low":25.17,"amount":703302.30516,"amplitude":0.067877,"askPrice":25.67,"askSize":450,"bidPrice":25.33,"bidSize":29,"shortable":3,"etf":0,"ttmEps":-2.338654,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1743019200000},"marketStatusCode":2,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":26.43,"preHourTrading":{"tag":"盘前","latestPrice":25.6524,"preClose":26.43,"latestTime":"08:00 EDT","volume":6,"amount":154.302,"timestamp":1742990437778},"postHourTrading":{"tag":"盘后","latestPrice":26.43,"preClose":26.43,"latestTime":"17:18 EDT","volume":5609,"amount":148225.51,"timestamp":1742937508512},"volumeRatio":0.3219},"requestUrl":"/m/hq/s/LENZ/wiki","defaultTab":"wiki","newsList":[{"id":"2522800575","title":"Avalo Therapeutics Names Michael Heffernan as Board Chairman","url":"https://stock-news.laohu8.com/highlight/detail?id=2522800575","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522800575?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 22:18","pubTimestamp":1742998714,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics  said Wednesday that Michael Heffernan has been named board chairman, succeeding Garry Neil.Neil will continue as chief executive officer and board member, the company said.Heffernan is the founder and chairman of Collegium Pharmaceutical ,  where he also previously served as president and CEO, Avalo said.Avalo shares were more than 3% higher in recent trading.Price: 8.72, Change: +0.18, Percent Change: +2.12","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AVTX","BK4007","COLL","BK4139","LENZ"],"gpt_icon":0},{"id":"2522802854","title":"Adaptimmune Therapeutics Is Maintained at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2522802854","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522802854?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 21:50","pubTimestamp":1742997000,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ADAP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 26, 2025 09:50 ET (13:50 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","ADAP"],"gpt_icon":0},{"id":"2522805787","title":"Acrivon Therapeutics Price Target Maintained With a $17.00/Share by Citizens Capital Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2522805787","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522805787?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 21:10","pubTimestamp":1742994600,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ACRV/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 26, 2025 09:10 ET (13:10 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","ACRV"],"gpt_icon":0},{"id":"2522805694","title":"Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2522805694","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522805694?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 21:00","pubTimestamp":1742994000,"startTime":"0","endTime":"0","summary":"CORAL GABLES, Fla., March  26, 2025  (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, or “the Company”), a clinical-stage biotechnology company committed to advancing innovativ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/26/3049732/0/en/Relmada-Therapeutics-to-Report-Fourth-Quarter-2024-Financial-Results-on-Thursday-March-27-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LENZ"],"gpt_icon":0},{"id":"2522805388","title":"Evofem announces license and supply agreement with Windtree Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2522805388","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522805388?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 20:55","pubTimestamp":1742993732,"startTime":"0","endTime":"0","summary":"Evofem Biosciences (EVFM) announced that it has entered into a License and Supply Agreement with Windtree Therapeutics (WINT), under which Windtree...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/evofem-announces-license-and-supply-agreement-with-windtree-therapeutics?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/evofem-announces-license-and-supply-agreement-with-windtree-therapeutics?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","WINT","BK4584","BK4007","LENZ","EVFM"],"gpt_icon":0},{"id":"2522805877","title":"MindBio Therapeutics Expands Capabilities with Acquisition of Life AI","url":"https://stock-news.laohu8.com/highlight/detail?id=2522805877","media":"TIPRANKS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522805877?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 20:47","pubTimestamp":1742993250,"startTime":"0","endTime":"0","summary":"Mindbio Therapeutics Corp. ( ($TSE:MBIO) ) has shared an update. MindBio Therapeutics Corp. has acquired Life AI Corp. Pty. Ltd., a company with te...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mindbio-therapeutics-expands-capabilities-with-acquisition-of-life-ai?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mindbio-therapeutics-expands-capabilities-with-acquisition-of-life-ai?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139"],"gpt_icon":0},{"id":"2522805352","title":"Stifel Nicolaus Keeps Their Hold Rating on HLS Therapeutics Inc (HLS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2522805352","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522805352?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 20:45","pubTimestamp":1742993104,"startTime":"0","endTime":"0","summary":"In a report released today, Justin Keywood from Stifel Nicolaus maintained a Hold rating on HLS Therapeutics Inc (HLS – Research Report), with a pr...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-keeps-their-hold-rating-on-hls-therapeutics-inc-hls-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-keeps-their-hold-rating-on-hls-therapeutics-inc-hls-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","SF"],"gpt_icon":0},{"id":"2522810870","title":"Leap Therapeutics Says New Data Show Sirexatamab Improves Survival in Colorectal Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2522810870","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522810870?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 20:31","pubTimestamp":1742992311,"startTime":"0","endTime":"0","summary":"Leap Therapeutics  said Wednesday that updated findings from its phase 2 trial indicate that sirexatamab combined with bevacizumab and chemotherapy improves progression-free survival and overall response rate in patients with advanced colorectal cancer.Leap reported that patients with elevated DKK1 protein levels who were treated with sirexatamab in addition to bevacizumab and chemotherapy had a 32% higher overall response rate and lived 3.5 months longer without their cancer worsening compared with patients receiving only bevacizumab and chemotherapy.The company also said that patients who had not previously received anti-VEGF therapy saw a 22% higher ORR and lived 2.6 months longer without disease progression, though overall survival data is still being collected.The company said the new data supports plans to move sirexatamab into a phase 3 trial, focusing on colorectal cancer patients with elevated DKK1 protein levels or no prior anti-VEGF therapy.The company's shares were up more ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4505","BK4563","LPTX","LENZ"],"gpt_icon":0},{"id":"2522963805","title":"Coya Therapeutics Reports Progress from an Academic Supported First-in-Class Treg-derived Exosome Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2522963805","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522963805?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 20:15","pubTimestamp":1742991300,"startTime":"0","endTime":"0","summary":"Regulatory T cell-derived exosomes  have demonstrated strong and consistent therapeutic potential in suppressing inflammation in preclinical models of neurodegenerative diseases as previously published here. Treg exosomes are end-stage differentiated, making them less likely to be affected by pro-inflammatory factors that may impact their suppressive function. The work planned includes GMP processes and manufacturing activities and the production of larger-scale clinical batches in the fourth quarter of 2025, in preparation for a first in human study. Coya’s previous research demonstrated that ex vivo expanded Treg exosomes express key immunoregulatory markers and effectively suppress pro-inflammatory responses in vitro. Treg exosomes are highly suppressive on pro-inflammatory macrophages and responder T cells. Additionally, Treg exosomes have advantages over Tregs in that they are taken up by myeloid cells that drive disease progression, and they are resistant to conversion to a non-s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/coya-therapeutics-reports-progress-academic-121500976.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","PRGS","LU2065732104.USD","BK4097","LENZ","COYA"],"gpt_icon":0},{"id":"2522387752","title":"BrainStorm Cell Therapeutics Granted Compliance Extension from Nasdaq","url":"https://stock-news.laohu8.com/highlight/detail?id=2522387752","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522387752?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 20:15","pubTimestamp":1742991300,"startTime":"0","endTime":"0","summary":"NEW YORK, March 26, 2025 /PRNewswire/ --BrainStorm Cell Therapeutics Inc. , a leading biotechnology company committed to the development and commercialization of best-in-class autologous cellular therapies for the treatment of neurodegenerative diseases, today announced that it has been granted the exact compliance extension it requested from the Nasdaq Hearings Panel through June 30, 2025, to regain compliance with certain continued listing standards of The Nasdaq Capital Market.BrainStorm presented its request for continued listing on The Nasdaq Capital Market and the relevant compliance plan to the Nasdaq Hearings Panel at the panel hearing held on February 25, 2025. As a result of the hearing, the Nasdaq Hearings Panel granted BrainStorm an extension until June 30, 2025 to regain compliance with certain continued listing standards. The grant of such exception reflects BrainStorm's commitment to executing its compliance plan to meet the applicable requirements within the specified t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/brainstorm-cell-therapeutics-granted-compliance-121500407.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/brainstorm-cell-therapeutics-granted-compliance-121500407.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PSQ","QLD","LU1363072403.SGD","BCLI","LU0267386448.USD","LU0006306889.USD","LU1162221912.USD","MNQmain","LU0314104364.USD","BK4534","LU1720051017.SGD","BK4588","IE00BZ1G4Q59.USD","LU1720051108.HKD",".IXIC","LU1989772840.SGD","IE00BGHQF748.EUR","LU0795875169.SGD","TQQQ","USJW.SI","BK4127","NDAQ","LU1668664300.SGD","LU2089284900.SGD","LU2357305700.SGD","NQmain","LU0106831901.USD","LU1548497426.USD","IE00B3QW5Z07.USD","TSYW.SI","BK4504","LU0795875086.SGD","LU1074936037.SGD","LU2271345857.HKD","USAW.SI","LU2095319765.USD","LU0912757837.SGD","LU2210150020.SGD","LU1732800096.USD","LENZ","LU2133065610.SGD","LU2347655156.SGD","NVIW.SI","LU0098860793.USD","BK4139","QID","LU2210149790.SGD","QQQ","SQQQ","LU0106261372.USD"],"gpt_icon":0},{"id":"2522951874","title":"Summit Therapeutics Raised to Buy From Neutral by Citigroup","url":"https://stock-news.laohu8.com/highlight/detail?id=2522951874","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522951874?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 20:02","pubTimestamp":1742990520,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SMMT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 26, 2025 08:02 ET (12:02 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SMMF","LENZ","SMMT"],"gpt_icon":0},{"id":"2522874474","title":"Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Announces its Novel Inhibitors Show Promising In Silico Activity Against Measles and Related Viruses","url":"https://stock-news.laohu8.com/highlight/detail?id=2522874474","media":"GlobeNewswire","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522874474?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 20:00","pubTimestamp":1742990400,"startTime":"0","endTime":"0","summary":"These candidates, previously shown to be active in vitro against respiratory syncytial virus  and human parainfluenza virus 3 , show the potential for Decoy’s novel platform to address both significant commercial opportunities and emerging viral threats with a single molecule. “Our proprietary peptide-conjugate technology platform for antivirals and cancer drug discovery, IMP3ACT, is adaptable in antivirals to develop potential treatments for existing viral diseases and new viral threats. I am proud of the Decoy team and their rapid in silico design of a drug candidate that is broadly active against multiple viruses, including RSV, hPIV, measles, Nipah and likely others. With this compound, we are developing a highly topical engineering application using Decoy’s platform technology and we are just getting started,” stated Decoy’s Co-founder and Chief Executive Officer Rick Pierce.“By integrating machine learning algorithms and molecular dynamics modeling in peptide design and synthesis","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/salarius-pharmaceuticals-merger-partner-decoy-120000632.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","SLRX","LENZ","ML","BK4166"],"gpt_icon":0},{"id":"2522087468","title":"Press Release: Whitehawk Therapeutics Completes Strategic Transformation with Successful Closing of Sale of Aadi Subsidiary to Kaken Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2522087468","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522087468?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 20:00","pubTimestamp":1742990400,"startTime":"0","endTime":"0","summary":"Whitehawk Therapeutics Completes Strategic Transformation with Successful Closing of Sale of Aadi Subsidiary to Kaken Pharmaceuticals. This press release contains certain forward-looking statements regarding the business of Whitehawk Therapeutics that are not a description of historical facts within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on the Company's current beliefs and expectations and may include, but are not limited to, statements relating to: the Company's cash runway extending into 2028; the anticipated timing of the Company's development of its portfolio of ADC assets, including the expected timing regarding the commencement of IND-enabling studies and key clinical data readouts; expectations regarding the beneficial characteristics, safety, efficacy, therapeutic effects and the size of the potential targeted markets with respect to the Company's ADC assets; and the sufficiency of the Company's existing capita","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","LENZ","WHWK","BK4232","R","BK4139"],"gpt_icon":0},{"id":"2522887520","title":"S&P 500 Futures Decline In Premarket Trading; GameStop, Summit Therapeutics Lead","url":"https://stock-news.laohu8.com/highlight/detail?id=2522887520","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522887520?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 19:30","pubTimestamp":1742988600,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Barrons.com using technology from Automated Insights.With U.S. stock markets set to open in two hours, GameStop Corp. Cl A  was up 17.6% in pre-market trading, and Summit Therapeutics Inc.  was up 4.6%.Dollar Tree Inc. , Chewy Inc. Cl A , and Global-E Online Ltd.  were all posting gains of at least 3%. In early trading, Trex Co. Inc.  and Vertiv Holdings LLC  had posted declines, falling 4.9% and 3.4%, respectively.Meanwhile S&P 500 futures were down 0.05%, with futures for the Dow Jones Industrial Average rising 0.03%. The Cboe Volatility Index futures were up 0.17%.In commodities news, Brent crude oil futures were up 0.86%, and gold futures were up 0.19%. Bitcoin climbed 0.10% to $88,243.In yesterday's regular trading session, the S&P 500 was up 0.16%, while the Dow remained unchanged. Stocks in Asia were mixed overnight, with Japan's NIKKEI 225 Index up 0.65% and China's Shanghai Composite Index down 0.04%.U.S. stock markets open for tradi","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8cb7288d64f129fb3c154af3ea33a10c","theme_name":"🔥TrendingNo.1 · GameStop's Investment in Bitcoin","theme_type":2,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139",".SPX","BK4577","GME","LU1941712264.USD","IE00BMPRXQ63.HKD","LU1093756325.SGD","BK4086","BK4096","IE00BMPRXN33.USD","BK4155","LU1064131342.USD","BK4585","LU1988902786.USD","LU2506951792.HKD","LU2264538146.SGD","LU0823414478.USD","BK4543","BK4200","BK4548","VOO","SMMT","BK4122","BK4588","DLTR","BK4220","TREX","LU1941712348.USD","CHWY","BK4114","BK4211","LU1093756168.USD","LU0823414551.USD","LU2249611893.SGD","LU2065731478.USD","VRT","BK4076","IE00BMPRXR70.SGD","LU2294711713.HKD","SMMF","IE00BN0W2T93.GBP","GLBE","BK4504","LU0006061336.USD","LU2357125470.USD","SPY","BK4547","BK4539","LENZ","IE00BN0W2W23.USD"],"gpt_icon":1},{"id":"2522187556","title":"Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2522187556","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522187556?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 19:05","pubTimestamp":1742987100,"startTime":"0","endTime":"0","summary":"Leap to host a conference call to present updated CRC clinical data today, March 26, 2025, at 8:00 a.m. ET. CAMBRIDGE, Mass., March 26, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. , a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2024.Reported positive updated data from Part B of the Phase 2 DeFianCe study of sirexatamab  in second-line patients with advanced microsatellite stable  colorectal cancer  confirming:. Statistically significant 22% higherORR and 2.6 month longer PFS in patients who had not had prior anti-VEGF therapy. FL-501 abstract accepted for poster presentation at the 2025 American Association for Cancer Research  Annual Meeting.Across the intent-to-treat population, thesirexatamab Experimental Arm had improved ORR compared to the Control Arm, with PFS and OS maturing with a higher number of patients continuing to","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/leap-therapeutics-reports-fourth-quarter-110500189.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/leap-therapeutics-reports-fourth-quarter-110500189.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0348723411.USD","BK4113","CRC","OS","LPTX","BK4097","BK4211","LU0266512127.USD","LENZ","IE00BMPRXQ63.HKD","IE00BMPRXN33.USD","ORR","BK4585","MSS","BK4141","BK4505","BK4588","BK4139","IE00BMPRXR70.SGD","BK4609","BK4563","LU0456854461.SGD","BK4543","BK4195","PFS","BK4213"],"gpt_icon":1},{"id":"2522596875","title":"Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2522596875","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522596875?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 19:00","pubTimestamp":1742986800,"startTime":"0","endTime":"0","summary":"Updated data confirms statistically significant 32% higher ORR and 3.5 month longer PFSin second-line CRC patients with high DKK1 levels treated with sirexatamab plus bevacizumab and chemotherapy. Statistically significant 22% higher ORR and 2.6 month longer PFSin patients who had not had prioranti-VEGF therapy. Leap to host a conference call to present clinical data today, March 26, 2025, at 8:00 a.m. ET. \"The updated data from Part B of the DeFianCe study presented today confirms that sirexatamab can generate significantly higher ORR and longer PFS in CRC patients who have high levels of DKK1 or who have not had prior anti-VEGF therapy, two exploratory populations with strong scientific rationale. In the full intent-to-treat population, sirexatamab demonstrated a higher ORR and a tail population with longer PFS that continues to mature. With more sirexatamab-treated patients currently continuing on study drug than control arm patients, there is potential for the dataset to continue t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/leap-therapeutics-reports-positive-updated-110000183.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/leap-therapeutics-reports-positive-updated-110000183.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0456854461.SGD","BK4213","BK4097","BK4195","ORR","BK4585","BK4211","IE00BMPRXN33.USD","PFS","IE00BMPRXQ63.HKD","BK4505","LENZ","BK4563","BK4141","BK4543","BK4113","BK4588","OS","LU0266512127.USD","ARM","BK4139","IE00BMPRXR70.SGD","MSS","CRC","LU0348723411.USD","LPTX","BK4609"],"gpt_icon":0},{"id":"2522201998","title":"Press Release: Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2522201998","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522201998?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 19:00","pubTimestamp":1742986800,"startTime":"0","endTime":"0","summary":"WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025  -- Avalo Therapeutics, Inc. , a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors . Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer  of the Company.\"We are thrilled to welcome Michael to Avalo's Board of Directors during this pivotal time in our Company's growth,\" said Dr. Garry Neil, CEO of Avalo Therapeutics. \"Michael's extensive experience in building and leading biopharmaceutical companies, executing successful exits, and driving shareholder value will be invaluable as we advance our pipeline of targeted therapies for immune-mediated diseases, including our lead candidate, AVTX-009, currently in the Phase 2 LOTUS trial for hidradenitis suppurativa . Additionally, I believe it is the right time to separate the role of Chairman an","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CEO","BHVN","LU1093756168.USD","AVTX","LENZ","BK4139","LU1093756325.SGD","NQmain"],"gpt_icon":0},{"id":"2522278820","title":"This CRISPR Therapeutics Insider Increased Their Holding In The Last Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2522278820","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522278820?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 18:33","pubTimestamp":1742985225,"startTime":"0","endTime":"0","summary":"Insiders were net buyers of CRISPR Therapeutics AG's  stock during the past year. That is, insiders bought more stock than they sold.Although we don't think shareholders should simply follow insider transactions, we do think it is perfectly logical to keep tabs on what insiders are doing.The Last 12 Months Of Insider Transactions At CRISPR Therapeutics. Insider purchases may have been minimal, in the last three months, but there was no selling at all. Overall the buying isn't worth writing home about. However, our analysis of transactions over the last year is heartening. Insiders own shares in CRISPR Therapeutics and we see no evidence to suggest they are worried about the future. In addition to knowing about insider transactions going on, it's beneficia","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/crispr-therapeutics-insider-increased-holding-103345564.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","LU1861558580.USD","LU1861559042.SGD","BK4611","BK4588","BK4139","CRSP","BK4585","BK4556"],"gpt_icon":0},{"id":"2522821171","title":"Aprea Therapeutics Full Year 2024 Earnings: Beats Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2522821171","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522821171?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 18:05","pubTimestamp":1742983543,"startTime":"0","endTime":"0","summary":"This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.NasdaqCM:APRE Earnings and Revenue History March 26th 2025. All figures shown in the chart above are for the trailing 12 month  period. Revenue exceeded analyst estimates by 12%. Earnings per share  also surpassed analyst estimates by 7.7%.Looking ahead, revenue is forecast to grow 53% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US.The company's shares are down 7.6% from a week ago.We should say that we've discovered 5 warning signs for Aprea Therapeutics (1 is potentially serious!) that you should be aware of before investing here.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aprea-therapeutics-full-2024-earnings-100543074.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["APRE","LENZ"],"gpt_icon":0},{"id":"2522082510","title":"Citigroup Upgrades Summit Therapeutics to Buy From Neutral, Adjusts Price Target to $35 From $23","url":"https://stock-news.laohu8.com/highlight/detail?id=2522082510","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522082510?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 18:01","pubTimestamp":1742983305,"startTime":"0","endTime":"0","summary":"Summit Therapeutics (SMMT) has an average rating of buy and mean price target of $35.50, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SMMF","SMMT","LENZ"],"gpt_icon":0}],"profile":{"websiteUrl":"http://ir.graphitebio.com","stockEarnings":[{"period":"1week","weight":0.0832},{"period":"1month","weight":0.1252},{"period":"3month","weight":-0.161},{"period":"6month","weight":0.1879},{"period":"1year","weight":0.6195},{"period":"ytd","weight":-0.0845}],"compareEarnings":[{"period":"1week","weight":0.0257},{"period":"1month","weight":-0.0408},{"period":"3month","weight":-0.043},{"period":"6month","weight":0.0055},{"period":"1year","weight":0.1071},{"period":"ytd","weight":-0.0181}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.169631},{"month":2,"riseRate":0.5,"avgChangeRate":0.077415},{"month":3,"riseRate":0.25,"avgChangeRate":-0.090593},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.06634},{"month":5,"riseRate":0,"avgChangeRate":-0.187229},{"month":6,"riseRate":0.666667,"avgChangeRate":0.07217},{"month":7,"riseRate":0.5,"avgChangeRate":0.062427},{"month":8,"riseRate":0.25,"avgChangeRate":-0.053734},{"month":9,"riseRate":0.5,"avgChangeRate":-0.017856},{"month":10,"riseRate":0.75,"avgChangeRate":0.006056},{"month":11,"riseRate":0.5,"avgChangeRate":-0.013543},{"month":12,"riseRate":0.5,"avgChangeRate":0.070925}],"exchange":"NASDAQ","name":"Therapeutics","nameEN":"Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Therapeutics(LENZ) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Therapeutics,LENZ,Therapeutics股票,Therapeutics股票老虎,Therapeutics股票老虎国际,Therapeutics行情,Therapeutics股票行情,Therapeutics股价,Therapeutics股市,Therapeutics股票价格,Therapeutics股票交易,Therapeutics股票购买,Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Therapeutics(LENZ) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction